CV Dominik Wolf (June 2015)

CV Dominik Wolf (June 2015)
Education
July 92
Okt. 92 – Jan 94
May 94 – Oct. 2000
Abitur, Goldberg-Gymnasium Sindelfingen
Civil Service at the Institute for Radiology, University
Hospital Regenburg
Medical Training at the University of ErlangenNürnberg
MD Thesis:
Finished January 2002 with distinction („summa cum laude“), supported by the DFG
(Graduiertenkolleg).
Clinical Education:
February 2001-2007
Since August 2006
April 2007
Since March 2008
Since April 2008
Since April 2008
Since December 2009
Since October 2011
October 2012 to February 2013
October 2013 to May 2014
Since March 2012
Since September 2013
Since September 2013
Residency at the Department of Hematology and
Oncology, Medical University Innsbruck, Austria
Head of the Laboratory of Tumorimmunology at the
Department of Hematology and Oncology, Medical
University Innsbruck , Austria
Board certification Internal Medicine
Program Director for Chronic Myeloproliferative
Diseases at the Department of Hematology and
Oncology, Medical University Innsbruck , Austria
Privatdozent/PD (“venia legendi”) for Internal
Medicine, Medical University Innsbruck, Austria
Senior
physician
on
the
Bone
Marrow
Transplantation Unit
Board certification Hematology and Oncology
W2 Professor for Tumorimmunology and senior
physician,
Internal
Medicine
III,
Hematology/Oncology
and
Rheumatology,
University of Bonn, Germany
Head of ICU
Head of outpatient Hemato-Oncology Unit
Head of the Bone Marrow Transplant Program
(ongoing)
Head Clinical Trial Unit Med III (ongoing)
Deputy Director of Medical Department III (ongoing)
Research focus:
Immune regulation in cancer, stem cell transplantation and autoimmunity
Clinical focus:
Myeloid neoplasia (acute leukemia, MPN)
Lymphoma
Stem cell transplantation
Awards:
MD-thesis poster-award of the University of Erlangen-Nürnberg 2002
MD-thesis award by the Staedtler-Foundation 2002
Annual Award of the Austrian Society of Nephrology 2005
Schönmann Krebsforschungspreis 2007
Otto-Kraupp-Gedächtnispreis (Sanofi-Aventis Preis) 2009
OEGHO Young Investigator 2013 (Senior)
Ad hoc reviewing:
Journals:
The Lancet, Leukemia, Gut, Cancer Res, Cell Death Differentiation, Journal of
the American Society of Nephrology, Clin Cancer Res, Oncoimmunology,
Haematologica, Molecular Cancer Therapeutics, Oncotarget, Crit Rev Haematol
Oncol, Exp Rev Haematology, Exp Rev Anticancer Ther, Int J Cancer, Br J
Haematol, J Leuk Biol, PLOS One, Gastric Cancer, Cytotherapy. Br J Cancer,
Cancer Letters, Cancer Immunol Immunother, Current Cancer Drug Targets, J
Thoracic Oncology, Exp Opin Exper Ther, FEBS Letters, Exp. Gerontol, Eur J
Heamtol, Clinical and Vaccine Immunology, Liver International, Current Stem Cell
Research & Therapy, Gynecol Oncol, Journal of Cancer Research and Clinical
Oncology, Int J Gynecological Cancer, Leukemia Res, Scientific Reports,
Leukemia and Lymphoma, Eur J Clin Invest
Funding agencies:
Cancer Research UK
Deutsche Forschungsgemeinschaft (DFG)
Swiss National Science Foundation
Forschungsfonds der Österreichischen Nationalbank
L’Oreal Foundation
American University of Beirut
Tiroler Wissenschaftsfonds
DAAD
Wilhelm-Sander Stiftung
Memberships:
American Society of Hematology (ASH)
European Society of Hematology (EHA)
German Society of Hemato-Oncology (DGHO)
Austrian Society of Hematology and Oncology (ASHO), Former Scientific Board
Member
Patents:
Co-applicant:
METHOD
FOR
INCREASING
IMMUNOREACTIVITY
(WO/2009/073905)
Co-applicant: METHOD FOR DETERMNING CBL-B EXPRESSION
(WO/2010/119061 A1)
Clinical Trials:
PI of numerous academic and industry-sponsored Phase I to III clinical trials
Varia:
Member of the lead group of the German Study Group-MPN (GSG-MPN)
Executive Committee of the Central European Leukemia Study Group (CELSG)
Task Force Infektiologie UKB
Arzneimittelkomission UKB
Arbeitsgruppe Antbiotika des UKB
Clinical study board of the UKB
Quality Board UKB
Guest Editor Current Cancer Drug Targets
Editorial Board International Journal of Stem Cell Research
Funding:
Peer review
DFG, FFG, OENB, OEGHO, Bonfor, MFF Tirol, Krebshilfe Tirol
Industrial
Novartis, Roche, AOP, Pfizer, Amgen, Ariad